A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- PMID: 20038235
- DOI: 10.3109/10428190903440946
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
Abstract
Despite advances in therapy, chronic lymphocytic leukemia remains an incurable disease and novel, effective therapies are needed. In this open-label, dose-escalation, phase I study, dacetuzumab (IgG1 humanized monoclonal antibody) was administered to 12 adults, all of whom had received several prior systemic therapies (median, 4; range, 2-11). Intrapatient dose escalation (maximum weekly doses of 3-8 mg/kg) was used to diminish first-dose-related inflammatory symptoms. No dose-limiting toxicities or dose-dependent trends in adverse events (AEs) were observed. The most common AEs (in >/=2 patients) were fatigue, headache, anorexia, conjunctivitis, hyperhidrosis, and night sweats, all of which were mild or moderate. No deaths, serious AEs, or discontinuations due to AEs occurred. Although no patient achieved an objective response, five patients demonstrated stable disease after 1 cycle of therapy, with no discernable correlation between dacetuzumab dose and outcome. This modest single-agent activity may warrant further testing of dacetuzumab in combination with other chronic lymphocytic leukemia therapies.
Similar articles
-
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.J Clin Oncol. 2009 Sep 10;27(26):4371-7. doi: 10.1200/JCO.2008.21.3017. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636010 Clinical Trial.
-
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.J Hematol Oncol. 2014 Jun 12;7:44. doi: 10.1186/1756-8722-7-44. J Hematol Oncol. 2014. PMID: 24919462 Free PMC article. Clinical Trial.
-
A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.Haematologica. 2010 May;95(5):845-8. doi: 10.3324/haematol.2009.008003. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133895 Free PMC article. Clinical Trial.
-
Alemtuzumab: what is the secret to safe therapy?Clin Adv Hematol Oncol. 2011 May;9(5):364-73. Clin Adv Hematol Oncol. 2011. PMID: 21685865 Review.
-
Alemtuzumab in the treatment of chronic lymphocytic leukemia.BioDrugs. 2005;19(1):9-22. doi: 10.2165/00063030-200519010-00002. BioDrugs. 2005. PMID: 15691213 Review.
Cited by
-
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies.Oncol Lett. 2020 Nov;20(5):176. doi: 10.3892/ol.2020.12037. Epub 2020 Aug 31. Oncol Lett. 2020. PMID: 32934743 Free PMC article. Review.
-
Immunotherapy of cancer in 2012.CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. CA Cancer J Clin. 2012. PMID: 22576456 Free PMC article. Review.
-
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.Cancers (Basel). 2021 Jun 21;13(12):3084. doi: 10.3390/cancers13123084. Cancers (Basel). 2021. PMID: 34205588 Free PMC article.
-
Targeting costimulatory molecules to improve antitumor immunity.J Biomed Biotechnol. 2012;2012:926321. doi: 10.1155/2012/926321. Epub 2012 Feb 12. J Biomed Biotechnol. 2012. PMID: 22500111 Free PMC article. Review.
-
Targeting CD8+ T-cell tolerance for cancer immunotherapy.Immunotherapy. 2014;6(7):833-52. doi: 10.2217/imt.14.51. Immunotherapy. 2014. PMID: 25290416 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
